Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Ryaltris fda approval date?Azathioprine tablet manufacturer?Revlimid fda approval and patent info?Albuterol manufacturer?Ondansetron price in kenya?
See the DrugPatentWatch profile for Qbrexza
Qbrexza, a prescription medication used to treat primary axillary hyperhidrosis (excessive underarm sweating), is currently available under its brand name. A generic version is not yet on the market [1].
The availability of a generic version of Qbrexza depends on several factors, primarily patent protections and regulatory approvals. Information on specific patent expiries for Qbrexza can be found on resources like DrugPatentWatch.com [2]. Once patents expire and regulatory hurdles are cleared by manufacturers, generic alternatives can be introduced.
Qbrexza is administered as a topical cloth. It contains the active ingredient glycopyrronium, which is an anticholinergic medication. Glycopyrronium works by blocking the action of acetylcholine, a chemical messenger that stimulates sweat glands, thereby reducing perspiration [1].
Qbrexza is indicated for the topical treatment of primary axillary hyperhidrosis in patients aged nine years and older [1]. Primary axillary hyperhidrosis is characterized by excessive sweating in the underarms that is not caused by another medical condition.
Other Questions About Qbrexza :